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Abstract
Background: Perinatal probiotics supplementation has been shown to be effective in the primary prevention
of atopic dermatitis (AD) in early childhood, although the long term effects of probiotics on AD and other
allergic diseases is less certain. We have previously reported a significant reduction in the cumulative
incidence of AD at 2 years after maternal probiotic supplementation. In this study we present the effects
of perinatal probiotics given to women from a general population on allergy related diseases in their offspring
at 6 years.
Methods: Four hundred and fifteen pregnant women were randomised to receive probiotic or placebo milk in
a double-blinded trial from 36 week gestation until 3 months postpartum. Probiotic milk contained Lactobacillus
rhamnosos GG, L. acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12. At 6 years, children were
re-assessed for AD, atopic sensitisation, asthma and allergic rhinoconjunctivitis (ARC).
Results: At 6 years, 81 and 82 children were assessed for AD in the probiotic and placebo groups, respectively.
In a multiple imputation analysis, there was as trend towards a lower cumulative incidence of AD in the
probiotic group compared to the placebo group (OR 0.64, 95 % CI 0.39-1.07, p = 0.086; NNT = 10). This finding
was statistically significantly in the complete case analysis (OR 0.48, 95 % CI 0.25-0.92, p = 0.027, NNT = 6). The
prevalence of asthma and atopic sensitisation, and the cumulative incidence of ARC were not significantly
affected by the probiotic regime at 6 years of age.
Conclusions: Maternal probiotic ingestion alone may be sufficient for long term reduction in the cumulative
incidence of AD, but not other allergy related diseases.
Trial registration: ClinicalTrials.gov identifier: NCT00159523
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Background
Atopic dermatitis (AD), asthma and allergic rhinocon-
junctivitis (ARC) are a major cause of chronic disease in
childhood. A revised version of the “hygiene hypothesis”
suggests that the pattern of colonisation and the diver-
sity of the intestinal microbiota may be an important
factor in the increased prevalence of these diseases
observed over the past several decades [1–3]. Subse-
quently, probiotics have been investigated in the preven-
tion and treatment of allergy related diseases [3–8], with
the strongest evidence emerging for the primary preven-
tion of atopic dermatitis [3–5]. Throughout this paper
we refer AD, asthma and ARC as “allergy related dis-
eases”, recognising that not all presentations of these
conditions are related to a classic IgE-mediated inflam-
matory process.
Randomised controlled trials (RCTs) testing probiotics
in the prevention of childhood allergy related disease are
heterogeneous and have used a variety of bacterial strains,
administration regimes and varying ages of follow-up.
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Using information from the first published follow up for
each trial, a recent meta-analysis concluded that probiotic
administration is protective against the development of
AD in infancy [3]. Among the studies with follow-up at or
beyond 5 years of age, the greatest protective benefit of
probiotics against AD appears to be in early childhood
and it is less certain if this effect persists until school age
[9–25]. Only one of these studies did not specify a mater-
nal or family history of atopy as an inclusion criteria [9,
10], and there is therefore a particular need for further
longer term follow-up studies to determine the ongoing
effect of perinatal probiotics in general populations.
The Probiotics in the Prevention of Allergy among
Children in Trondheim (ProPACT) study is a double-
blinded RCT investigating the effect of maternal
probiotic supplementation on childhood allergy related
diseases in a general population. The initial results of
the ProPACT study demonstrated a clinically significant
reduction in the cumulative incidence of AD at 2 years
(OR 0.51, 95 % CI 0.30 – 0.87, p = 0.013), with the great-
est reduction seen in children not considered at “high
risk” for allergy related disease based on a negative fam-
ily history [26]. Probiotic supplementation did not sig-
nificantly affect the incidence of asthma, ARC or atopic
sensitisation at 2 year of age, although the diagnosis of
the former two diseases is uncommon and controversial
at such a young age.
The participating children were re-contacted and re-
assessed at 6 years of age for the presence of allergy re-
lated diseases and allergic sensitisation. The aim of the
current paper was to investigate the effect of maternal
perinatal probiotic supplementation on the cumulative
incidence of AD and ARC and prevalence of asthma and
atopic sensitisation at 6 years of age.
Methods
Participants and design
The ProPACT study has been described in detail previ-
ously [26]. Briefly, 415 women living in Trondheim,
Norway, were randomised to receive daily probiotic sup-
plementation or placebo from 36 weeks gestation until
3 months postpartum. Probiotic supplementation con-
sisted of 250 mL of low fat fermented milk containing
5 × 1010 colony-forming units (CFUs) of Lactobacillus
rhamnosus GG (LGG) and Bifidobacterium animalis
subsp. lactis Bb-12 (Bb-12) and 5 × 109 CFU of L. acid-
ophilus La-5 (La-5). The equivalently tasting placebo
milk was sterile and contained no probiotic bacteria.
The study milk was consumed by the women both pre-
and postnatally, and the children did not receive any
probiotic supplementation as a part of this study.
Participants were requested to complete questionnaires
regarding lifestyle factors during pregnancy and at 6 weeks,
1 year and 2 years postpartum. These questionnaires
detailed family history of allergy related diseases, dietary
and parental smoking habits, housing conditions, family
structure and the general health of the children. A child
health questionnaire focusing on the presence of allergic
symptoms and antibiotic use was completed at 1, 2 and
6 years. Information regarding mode of delivery was un-
available, although assumed to be unaffected by the inter-
vention regime. Those who had not initially responded to
the 6 year child health questionnaire were re-sent this
questionnaire in October 2013, when the children were be-
tween 8 and 10 years of age and responders to this re-sent
questionnaire were considered “late responders”.
Families were encouraged to attend a clinical examin-
ation for AD prior to 1 year if the child developed an
itchy rash which lasted for more than 4 weeks. At 2 and
6 years, all children were invited to attend a clinical
examination, including a structured interview, and al-
lergy testing consisting of skin-prick testing (SPT) and
specific IgE (sIgE). This examination was conducted by
specially trained nurses at the 6 year follow-up who were
unaware of treatment allocation. Participants were un-
blinded after the publication of the 2 year follow-up re-
sults [26]. Prior to this, the participants and investigators
were blinded to treatment allocation which was con-
ducted by the Department of Applied Clinical Research
at the Norwegian University of Science and Technology
through a computer-generated randomisation list with-
out restrictions.
The trial was approved by the Regional Committee for
Medical Research Ethics for Central Norway (Ref. 097–
03) and the Norwegian Data Inspectorate (Ref. 2003/
953-3 KBE) and the trial protocol is registered in Clini-
calTrials.gov (identifier NCT00159523). Parents gave
their written consent.
Outcomes
The primary outcomes of interest were: cumulative inci-
dence of atopic dermatitis (AD) and allergic rhinocon-
junctivitis (ARC), and the 12 month prevalence of
asthma. Children who attended the clinical examina-
tion(s) were assessed for AD using the UK Working
Party (UKWP) diagnostic criteria [27]. Children who
were assessed under these criteria as having AD at any
point up to 6 years were considered to ever have had
AD in the cumulative incidence estimate.
The cumulative incidence of ARC was defined by a
positive answer to the question “Has your child ever had
hay fever or allergic rhinoconjunctivitis?” in the 1, 2 or
6 year questionnaire. Current asthma was defined as a
positive answer to both questions “Has your child ever
been diagnosed with asthma by a doctor?” and “In the
past 12 months, has your child been treated with tablets,
inhalers or other medications for wheezing, chest tight-
ness or asthma?”. These questionnaire based definitions
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were used in order to minimise the proportion of partic-
ipants with missing data and vary from the clinical
examination based definitions presented in the 2 year
follow-up article (Additional file 1: Table S1). Prompted
by the findings of other probiotic trials, we include here
the cumulative incidence of wheeze defined by a positive
answer to both questions “Has your child ever had
whistling in the chest?” and “Has your child ever had ep-
isodes of wheezing or tightness in the chest?” and a his-
tory of a lower respiratory tract infection, subcategorised
into bronchitis and pneumonia, in the 1, 2 or 6 year
questionnaire.
Atopic sensitisation was assessed as a secondary end-
point and was defined as any SPT wheal ≥ 3 mm or any
sIgE level ≥ 0.35kUL−1. Both SPT and sIgE testing was
performed as described previously [26] according to the
ISAAC II procedure [28] for the following allergens:
mite, mould, cat and dog dander, birch, timothy (grass)
and mugwort pollen, egg white, codfish, hazelnut, pea-
nut and cow’s milk.
Statistical analysis
All statistical analyses were conducted using Stata/IC 13.1.
The sample size calculation and randomisation procedure
has been previously reported [26]. Due to the presence of
missing data, the intention to treat (ITT) analysis strategy
[29] included a main analysis using multiple imputations
by chained equations (MICE) under the assumption that
the data is missing at random (MAR) and a pattern mix-
ture model (PMM) analysis to assess the sensitivity of the
conclusions to this assumption. One hundred (m = 100)
imputed data sets were created for the MICE analysis
using the following predictor variables: treatment alloca-
tion, family history of atopy, siblings, sex, paternal smok-
ing, antibiotic use within the first year of life, parentally
reported eczema, protocol compliance and disease out-
comes at 2 and 6 years of age. Further details regarding
the MI model are provided in Additional file 1. A
complete case analysis is also presented which includes
participants who submitted the 6 year health question-
naire and or attended the 6 year clinical interview.
Univariate logistic regression was used to assess the
impact of maternal probiotic supplementation on each
of the outcomes for both multiple imputed datasets and
complete case analyses. Although potential confounders
should be balanced in an RCT, an alternate logistic re-
gression model including family history, sex and siblings
was assessed because of their previously reported associ-
ations with allergic disease and slight imbalance in the
latter two.
A missing not at random (MNAR) sensitivity analysis
was conducted using the pattern-mixture model version
of the user written Stata command rctmiss. A detailed




Participating families were recruited between September
2003 and September 2005, and the initial 6 year follow
up occurred from December 2009 to December 2011.
The 6 year child health questionnaire was completed by
281 (67.7 %) families and 163 (39.3 %) attended the clin-
ical interview (Fig. 1), with no significant difference in
attendance rates between the probiotic and placebo
groups. Mean age of follow-up at the clinical examin-
ation was 6.3 years (SD 0.2 years) in both probiotic and
placebo arms. The mean age of completion of the ques-
tionnaire was also comparable between treatment arms
among both initial and late responders (data not shown).
The baseline data and characteristics of participants
randomised to receive probiotic supplementation or pla-
cebo showed minimal differences between the treatment
groups (Table 1). Differences considered to be of poten-
tial influence due to reported association with childhood
allergic diseases included the higher proportion of males
(49.7 vs 41.8 %) and children with older siblings (44.0 vs
39.0 %) in the probiotic group compared to the placebo
group.
Characteristics of participants followed-up at 6 years
Compared to those lost to clinical follow up, the children
who attended the 6 year clinical examination had older
mothers, were less likely to have a father who smoked dur-
ing their first year of life and to have received fish before
6 months of age, and were more likely to have a family
history of atopy, an older sibling and study protocol com-
pliance (Table 1). Additionally, the children sensitised and
or diagnosed with AD at 2 years were more likely to have
attended the 6 year examination (Table 1). Similar differ-
ences were observed between children with and without a
completed 6 year questionnaire (details provided in
Additional file 1: Table S2).
Atopic dermatitis
A trend towards a lower cumulative incidence of UKWP
diagnosed AD in the probiotic group with an odds ratio
(OR) of 0.64 (95 % CI 0.39-1.07, p = 0.086; NNT = 10)
was observed in the MICE analysis (Table 2). This find-
ing was statistically significantly in the complete case
analysis (OR 0.48, 95 % CI 0.25-0.92, p = 0.027; NNT =
6). The adjustment for the covariates family history, sex
and presence of older siblings resulted in inconsequen-
tial changes in the calculated OR estimates and did not
substantially improve the precision of the estimate (data
not shown).
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Allergic rhinoconjunctivitis, asthma, sensitisation and
lower respiratory tract infections
There was no statistically significant difference observed
between the cumulative incidence of ARC, 12 month
prevalence of asthma or current atopic sensitisation in
the MICE or complete case analyses (Table 2). Parental
reported cumulative incidence of wheeze and lower re-
spiratory tract infections were not influenced by the pro-
biotic regime in observed cases or imputed estimates.
There was a trend towards a lower cumulative incidence
of pneumonia in the probiotic group (OR 0.41, 95 % CI
0.17-1.04, p = 0.062, Table 2) which was not statistically
significant in the MICE analysis.
Sensitivity analysis
The results of the sensitivity analysis are provided in the
Additional file 1. Briefly, if children with AD were more
likely to be lost to follow-up in the probiotic group than
the placebo group, then the preventative effect of pro-
biotics would have been weakened.
Discussion
Maternal probiotic supplementation given to a general
population of women appears to have an ongoing pre-
ventative effect on the cumulative incidence of AD until
school age, however this did not reach statistical signifi-
cance in the MICE analysis. There was no observed
Fig. 1 Participant flow diagram. The exact number of women who were invited and or assessed for eligibility is not available. aSeveral children
were lost to both questionnaire and examination follow-up as displayed at the bottom of this box. bNumber of participants who moved from the
Trondheim municipality was estimated from public address catalogues
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Table 1 Baseline data, characteristics and allergy related disease at 2 years
Comparison of treatment groups Comparison of drop out cases
Probiotic (n = 211) Placebo (n = 204) Attended 6 yr examination Drop-outs
na na na na p-valueb
Baseline data and characteristics
Age, mother (years), mean ± SD 191 30.1 (3.9) 189 30.3 (4.4) 162 30.7 (3.9) 218 29.8 (4.2) 0.024
Education, mother (yrs), mean ± SD 183 15.3 (2.2) 181 15.2 (2.3) 156 15.2 (2.1) 208 15.2 (2.4) 0.968
Education, father (yrs), mean ± SD 184 14.8 (2.7) 179 14.7 (2.4) 156 14.7 (2.5) 207 14.8 (2.6) 0.561
Birth weight (g), mean ± SD 187 3662 (478) 176 3596 (474) 161 3626 (466) 202 3635 (486) 0.814
Sex (male), n (%) 193 96 (49.7) 191 80 (41.8) 163 76 (46.6) 221 100 (45.3) 0.151
Premature, n (%) 189 5 (2.7) 185 7 (3.8) 162 5 (3.1) 212 7 (3.3) 1.000c
Siblings, n (%) 207 91 (44.0) 200 78 (39.0) 163 82 (50.3) 244 87 (35.7) 0.003
Atopy in family, n (%) 207 152 (73.4) 200 148 (74.0) 163 127 (77.9) 244 173 (70.9) 0.115
Smoking motherd, n (%) 204 16 (7.8) 200 19 (9.5) 163 13 (8.0) 241 12 (9.1) 0.686
Smoking fatherd, n (%) 203 35 (17.2) 198 38 (19.2) 163 21 (12.8) 238 52 (21.8) 0.022
Breastfed ≥ 3 months, n (%) 168 164 (97.6) 166 162 (97.6) 155 153 (98.7) 179 173 (96.7) 0.293c
At least one pet at homed, n (%) 207 52 (25.1) 200 53 (26.5) 163 47 (28.8) 244 58 (23.7) 0.253
Used antibioticsd, n (%) 161 35 (21.7) 159 34 (21.4) 152 34 (22.4) 168 35 (20.8) 0.739
Fish ≤ 6 mo., n (%) 163 35 (21.5) 165 27 (16.4) 155 22 (14.2) 173 40 (23.1) 0.039
Vegetables ≤ 6 mo., n (%) 166 84 (50.6) 166 105 (63.3) 156 90 (57.7) 176 99 (56.3) 0.791
Protocol compliancee, n (%) 150 130 (86.7) 148 128 (86.5) 147 134 (91.2) 151 124 (82.1) 0.022
Allergy related disease at 2 years
Atopic dermatitis, n(%) 138 29 (21.0) 140 48 (34.3) 145 52 (35.9) 133 25 (18.8) 0.001
Allergic sensitisationf, n(%) 131 20 (15.3) 133 15 (11.3) 140 26 (18.6) 124 9 (7.3) 0.007
aN: number of observed cases for each variable differs based on the source of information; bp-values for attendees versus dropouts calculated using t-test for
continuous variables and χ2 for binary variables; cFisher’s exact test used to calculate p-values for binary variables with frequency <=5 in one or more cell of the
contingency table; dExposure to smoking, household pets or antibiotics reported anytime during the first year of life or during pregnancy; eCompliance defined as
consumption of 250 mL of study on ≥50 % of days, no consumption of other probiotic products and breast feeding for ≥ 3 months; fPositive skin prick test and or
specific IgE level, if only one negative test result was available, the child was considered not sensitised
Table 2 Prevalence and cumulative incidence at 6 years of allergy related diseases, wheeze and lower respiratory tract infections in
the probiotic and placebo groups
Imputed estimates Observed cases
Allergy related disease Probiotic, n=211 Placebo, n=204 Odds ratio (95 % CI)a Probiotic Placebo Odds ratio
% (95 % CI) % (95 % CI) n/n % (95 % CI) n/n % (95 % CI) (95 % CI)a
Current disease
Asthma 2.3 (0.0-4.7) 0.9 (0.0-2.5) 1.68 (0.21-13.20) 3/136 2.2 (0.7-6-7) 1/145 0.7 (0.0-4.8) 3.25 (0.33-31.6)
Allergic sensitisation 30.0 (21.2-38.8) 28.0 (18.8-37.1) 1.11 (0.62-1.96) 23/80 28.8 (19.7-39.8) 19/78 24.4 (16.0-35.3) 1.25 (0.62-2.54)
Cumulative incidence
Atopic dermatitis 29.3 (21.2-37.4) 39.1 (30.2-48.0) 0.64 (0.39-1.07)b 22/81 27.2 (17.3-37.1) 36/82 43.9 (32.9-54.9) 0.48 (0.25-0.92)c
ARC 21.6 (14.6-28.6) 18.8 (12.0-25.7) 1.19 (0.66-2.16) 22/134 16.4 (10.1-22.8) 20/145 13.8 (8.1-19.5) 1.22 (0.64-2.37)
Wheeze 39.0 (30.9-47.1) 45.8 (37.4-54.1) 0.75 (0.47-1.22) 46/132 34.9 (26.7-43.0) 55/142 38.7 (30.7-46.8) 0.85 (0.52-1.38)
LRTI (any) 30.6 (22.2-39.1) 36.8 (29.1-44.5) 0.76 (0.47-1.23) 33/128 25.8 (18.1-33.4) 40/138 29.0 (21.4-36.6) 0.85 (0.50-1.46)
Bronchitis 23.6 (16.3-30.9) 27.6 (20.2-35.0) 0.81 (0.48-1.36) 29/130 22.3 (15.1-29.5) 32/139 23.0 (16.0-30.1) 0.96 (0.54-1.70)
Pneumonia 10.2 (4.5-15.9) 15.4 (9.4-21.4) 0.61 (0.29-1.32) 7/129 5.4 (1.5-9.4) 17/141 12.1 (6.6-17.5) 0.42 (0.17-1.04)d
ARC: allergic rhinoconjunctivitis; LRTI: Lower respiratory tract infection; aUnadjusted logistic regression odds ratio; Significant or near significant p-values: bp=0.086,
cp=0.027 and dp=0.062
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effect of probiotics on the cumulative incidence of ARC,
the 12 month prevalence of asthma or current atopic
sensitisation.
A significant proportion of cases of allergy related dis-
eases occur in children who are otherwise considered
not to be at “high risk” and therefore primary prevention
strategies must also be assessed in general populations
[30]. This long term follow-up of the ProPACT trial is
an important addition to the literature concerning pro-
biotics in the prevention of allergic disease as one of few
studies to recruit participants from a general population
[7, 8, 29]. The only other RCT to have reported long
term follow-up in a general population observed no
benefit of their probiotic regime on the prevalence of
any allergic disease or the cumulative incidence of ques-
tionnaire defined AD at 8–9 years of age [9, 10]. Their
regime included Lactobacillus paracasei spp paracasei
F19 supplementation given to children during weaning.
In comparison, our study involved pre- and postnatal
supplementation of a mixture of probiotics which in-
cluded the L. rhamnosus GG (LGG) strain. Both LGG
and pre- and postnatal regimes were found to be associ-
ated with reduced RR of AD on sub-group analysis in a
meta-analysis [3]. Additionally, we report UK Working
Party diagnostic criteria defined AD which is a more ex-
tensively validated method of diagnosis [31, 32].
Looking to other trials, five RCTs have assessed the
cumulative incidence of AD at 5 years of age or beyond
in “high risk” populations [11–23]. The trial presented
by Kalliomaki et al. [11–13] and the Lactobacillus rham-
nosus (HN001) arm of the study by Wickens et al.
[14–16] report a significant reduction in the cumulative
incidence of AD, which is sustained, although reduced,
at follow-up at 6 years. Together with the current study,
these trials indicate that the beneficial effect of probio-
tics on AD is most pronounced in infancy and may con-
tinue into early childhood. Furthermore, they suggest
that we are observing a true primary preventative effect,
rather than an intervention which delays the onset of
AD. Contrastingly, the preventative effect of probiotics
seen at 2 years in the large RCT published by Kukkonen/
Kuitunen et al. [17, 18] showed no trend towards ongoing
benefit on follow-up at 5 years. The Bifidobacterium ani-
malis subsp. lactis (HN019) arm of Wickens et al. [14–16]
and 2 other trials [19–23] demonstrated no significant ef-
fect of probiotics on the cumulative incidence of AD at
any follow-up time point from 1 to 7 years of age. It is in-
teresting to note that all of the studies with an observed
ongoing effect administered a L. rhamnosus strain pre-
and postnatally, and that if the child was breastfed, the
postnatal supplementation was given solely to the mother
during the first months with the exception of Kalliomaki
et al. [11–13] where approximate 57 % of participants
opted to give the probiotic or placebo capsules directly to
the newborn children. In contrast, studies without an
ongoing effect have either administered probiotic spe-
cies other than L. rhamnosus and or specified that the
probiotic supplements were to be given directly to the
children regardless of breastfeeding. Further research
is required to investigate if these observations are coin-
cidental or represent strain and or regime specific
effects.
The lack of effect on asthma, ARC and atopic sensi-
tisation may reflect a true lack of effect or that the
current study is under-powered to observed smaller dif-
ferences in less frequent diseases. This is a universal
problem for probiotic trials reporting asthma as an out-
come [8]. Two recent meta-analyses concluded that
there is not enough evidence to support perinatal pro-
biotic supplementation in the prevention of childhood
asthma or wheeze [7, 8]. Reassuringly, neither our study
nor these meta-analyses found that probiotics increased
the risk of asthma or wheeze, a concern which arose
after long term follow-up by Kalliomaki et al. [8, 11]
Whilst one of these meta-analyses suggested that pro-
biotics may increase lower respiratory tract infections
[8], our study does not support this conclusion. On the
contrary, we observe a trend towards lower cumulative
incidence of pneumonia in the probiotic group. Atopic
sensitisation was found to be significantly reduced in a
sub-group meta-analysis of regimes which combined
pre- and postnatal administration [7]. Consistent with
the ProPACT study, none of the individual longer term
follow-up studies have observed a significant effect of
probiotics on sensitisation at school age. Interestingly,
Lactobacillus acidophilus was found to be associated
with an increased rate of atopic sensitisation in a multi-
variate meta-regression analysis [7]. This observation re-
quires further investigation and may, in part, explain the
lack of effect of the probiotic regime on sensitisation in
the ProPACT trial.
The major limiting factor of this RCT is the high pro-
portion of missing data which naturally raises concerns
regarding the generalisability of the results and introduc-
tion of bias. Following the four point ITT analysis strategy
recommended by White et al. [29] we have attempted to
follow-up all participants, performed a primary analysis
using MICE and a sensitivity analysis using PMM. Both of
the latter two models account for all randomised partici-
pants under a range of assumptions about the cause of
missingness and in doing so attempt to minimise bias
from covariate-related and outcome-related drop-out, re-
spectively. The reasons for loss to follow-up are primarily
unknown, however very few participants actively withdrew
from the study. An estimated 73 participants had moved
from the study region, which would have precluded their
attendance at the clinical examination in a presumably
random manner. A number of these participants were
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followed-up through the questionnaire. In terms of gener-
alisability, the original ProPACT population was similar to
the total PACT population, which in turn was representa-
tive of the general population in Trondheim, Norway [26].
At the 6 year follow-up, the remaining participants were
more likely to have a family history of atopy, older siblings
and a pet and less likely to have a father who smoked. As
these differences were not large we believe that the results
are still generalisable to westernised populations where
there is a reasonably high rate of allergy related disease.
The PMM sensitivity analysis is particularly pertinent in
this case because atopic sensitisation and or a diagnosis of
AD at 2 years are associated with both attendance at the
6 year clinical examination and a diagnosis of AD at
6 years. This raises suspicions that the data is partially
MNAR which would lead to biased estimates under both
the complete case and multiple imputations analysis
models. The PMM analysis suggests that results of this
study for ARC, asthma and atopic sensitisation would
have only been affected if there was an unrealistically
strong association between disease and missingness in a
single treatment arm. On the other hand, the magnitude
of the preventative effect attributed to probiotics for AD
at 6 years must be considered with caution, as the ob-
served benefit is sensitive to the assumption that the rela-
tionship between AD and loss to follow-up is essentially
identical in both the probiotic and placebo groups. Re-
gardless of whether the outcome variables are partially
MNAR, the MICE estimates are expected to be less biased
than the complete case analysis. Another limitation is that
the participants were informed of their treatment alloca-
tion and the observed reduction in AD after publication of
the results from the 2 year follow-up in 2010 [26], al-
though we do not believe that this to have significantly
affected the current results. Firstly, the knowledge of
treatment allocation has not affected participant behav-
iour with equal numbers from the probiotic and pla-
cebo groups attending the clinical follow-up at 6 years.
Secondly, the UKWP diagnosis was based on assess-
ment by research nurses who were unaware of treat-
ment allocation.
Conclusions
In conclusion, we have previously shown that perinatal
maternal probiotic supplementation is effective in redu-
cing the cumulative incidence of AD in children up to
2 years of age. The current study does not conclusively
demonstrate an ongoing benefit, however there is a
strong trend towards a reduced cumulative incidence at
6 years. This would suggest that perinatal probiotics pre-
vent and do not mere delay the onset of AD in child-
hood. The cumulative incidence of ARC and prevalence
of asthma and atopic sensitisation were unaffected by
the probiotic regime at 6 years of age.
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